Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risperdal Consta Once Monthly in Schizophrenia
NCT00236353Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2002
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of risperidone in schizophrenia and schizoaffective disorder, sponsored by Janssen Pharmaceutical. Primary endpoint: Incidence of symptom reoccurrence (relapse) at 1 year. Started May 2002; status: completed.
02
Drugs
risperidone
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT00236353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00236353.